RBC Europe’s Lexicon Pharmaceuticals LXRX Stock Holding History

RBC Europe’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,500	Closed	-$2.99K	–	1115
2020 Q2	$2.99K	Hold	1,500	–	–	﹤0.01%	918
2020 Q1	$2.92K	Hold	1,500	–	–	﹤0.01%	880
2019 Q4	$6.22K	Hold	1,500	–	–	﹤0.01%	882
2019 Q3	$4.51K	Hold	1,500	–	–	﹤0.01%	904
2019 Q2	$9.44K	Hold	1,500	–	–	﹤0.01%	812
2019 Q1	$8.34K	Hold	1,500	–	–	﹤0.01%	854
2018 Q4	$9.96K	Hold	1,500	–	–	﹤0.01%	786
2018 Q3	$16K	Hold	1,500	–	–	﹤0.01%	737
2018 Q2	$18K	Hold	1,500	–	–	﹤0.01%	698
2018 Q1	$12.9K	Hold	1,500	–	–	﹤0.01%	775
2017 Q4	$14.8K	Hold	1,500	–	–	﹤0.01%	753
2017 Q3	$18.4K	Buy	+1,500	New	+$22.2K	﹤0.01%	696

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

RBC Europe's LXRX Position: Q3 2020 in Review

RBC Europe sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2020, closing a stake of 1,500 shares — an estimated $2.99K sold.

RBC Europe first reported a position in LXRX in Q3 2017 and held it in 12 quarters. The position peaked at $18.4K in Q3 2017. 91 funds tracked by Wall St. Rank hold LXRX as of Q3 2020.

RBC Europe reported no remaining Lexicon Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
RBC Europe sold 1,500 Lexicon Pharmaceuticals shares in Q3 2020, an estimated $2.99K.
RBC Europe first reported a position in Lexicon Pharmaceuticals in Q3 2017 and held it in 12 quarters.
RBC Europe's Lexicon Pharmaceuticals position peaked at $18.4K in Q3 2017.
91 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2020.

Based on RBC Europe's 13F filing for Q3 2020, filed 9 Nov 2023.